The deep EPS miss and continued cash burn reinforce the pre-revenue, high-burn profile. Monitor PARADIGM trial enrollment updates and any future capital raise needs. The $320M raise provides a runway, but without near-term revenue catalysts, the stock may remain under pressure.
Price Chart
Executive Summary
Anteris Technologies reported Q1 2026 EPS of -$0.74, a 174% miss vs consensus of -$0.27, with revenue of $1.1M in line. The miss is driven by heavy R&D spending ($17.5M) and operating cash outflows of $28.7M to support the PARADIGM trial, though the company raised $320M in January to fund commercialization. The stock's historical pattern shows limited positive reaction to news, and the deep EPS miss with no revenue growth signals ongoing pre-commercial losses.
Key Financial Metrics
Key Facts
- EPS of -$0.74 missed consensus of -$0.27 by 174.1%
- Revenue of $1.1M in line with consensus, no YoY growth reported
- Net operating cash outflows of $28.7M in Q1 2026
- R&D expenses of $17.5M driven by PARADIGM trial and manufacturing scale-up
- Raised $320M in January 2026 to fund trial and commercialization
- U.S. enrollment in PARADIGM trial commenced post-quarter-end
- CMS coverage determination expected to support U.S. patient recruitment
Financial Impact
EPS miss of $0.47 vs consensus; operating cash burn of $28.7M in the quarter
Risk Factors
- Continued operating losses with no near-term revenue inflection
- Dilution risk from future capital raises if cash burn accelerates
- Clinical trial execution risk for PARADIGM
- Regulatory and commercial adoption risk for DurAVR THV
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293579 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | Insider Buy | $7.05 | awaiting T+20 | — | $5.78 (−18.01%) |
Oct 1, 2026 24d ago | Insider Buy | $7.71 | awaiting T+20 | — | $5.78 (−25.03%) |
Sep 23, 2026 4w ago | 8-K | $7.62 $6.01 | ▼ −21.13% | ▼ −21.82% | $5.78 (−24.15%) |
Sep 17, 2026 5w ago | 8-K | $8.16 $6.05 | ▼ −25.86% | ▼ −26.06% | $5.78 (−29.17%) |
Sep 16, 2026 5w ago | 3 | $8.37 $6.26 | ▼ −25.21% | ▼ −27.27% | $5.78 (−30.94%) |
Sep 8, 2026 6w ago | 8-K | $8.62 $7.05 | ▼ −18.21% | ▼ −20.18% | $5.78 (−32.95%) |
Aug 14, 2026 10w ago | Institutional Cluster | $9.42 $8.72 | ▼ −7.43% | ▼ −5.91% | $5.78 (−38.64%) |
Aug 11, 2026 10w ago | Press Release | $8.87 $8.30 | ▲ +6.43% | ▲ +4.53% | $5.78 (+34.84%) |
Jul 31, 2026 12w ago | 8-K | $7.84 $8.74 | ▲ +11.48% | ▲ +8.49% | $5.78 (−26.28%) |
Jul 28, 2026 12w ago | Insider Buy | $8.17 $8.89 | ▲ +8.81% | ▲ +5.43% | $5.78 (−29.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers